Advertisement

Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats

  • Jennypher Mudunuru
  • Chen Ren
  • David R. TaftEmail author
  • Manoj Maniar
Original Research Article
  • 21 Downloads

Abstract

Background and Objectives

ON 123300, a small molecule dual inhibitor of the c-MYC activated kinases ARK5 and CDK4/6, is being developed as a novel drug candidate for the treatment of cancer. The objective of this research was to evaluate gender differences in the in vitro metabolism and in vivo systemic exposure of ON 123300 in rats.

Methods

In vitro metabolism experiments (n = 2/group) were performed in rat liver microsomes from male and female donors. ON 123300 bislactate (final concentration 10 µM) was incubated with 0.5 mg/mL microsomes, and samples (100 µL) were withdrawn at specified incubation times over a period of 60 min, and immediately quenched and centrifuged. The supernatant was analyzed for ON 123300 and its metabolites by HPLC. ON 123300 (bislactate salt) pharmacokinetics were evaluated following intravenous (i.v.) (30 s infusion, 5 and 10 mg/kg) or oral administration (25 and 100 mg/kg) to male and female Sprague–Dawley rats (250–300 g). Following dosing, blood samples were collected over a time period up to 24 h. ON 123300 plasma concentrations were measured by LC–MS/MS. Pharmacokinetic parameters were estimated by non-compartmental analysis. Plasma and microsomal binding of ON 123300 and blood:plasma ratio were also determined.

Results

ON 123300 displayed more rapid microsomal degradation in vitro in males compared to females, as reflected in intrinsic clearance (181 vs 53.1 µL/min/mg). This translated into a significantly higher exposure of ON 123300 following oral administration to female rats, with the area under the curve (AUC) increasing nearly 3-fold (5617 ± 1914 ng·h/mL) compared to males (AUC = 1965 ± 749 ng·h/mL). This gender effect was less pronounced following i.v. dosing, where the AUC was ~ 2-fold higher in females. Based on these results, the higher plasma exposure observed in females can be primarily attributed to reductions in both hepatic clearance and presystemic metabolism compared to males.

Conclusions

This investigation demonstrated a significantly lower metabolism of ON 123300 in female rats, which resulted in high systemic exposure. Additional testing is warranted to assess the potential clinical implications of these findings.

Notes

Compliance and Ethical Standards

Funding

This research was funded by Onconova Therapeutics, Inc.

Conflict of interest

J. Mudunuru, no conflicts; C. Ren, employed by Onconova Therapeutics, Inc.; D. Taft, received grant support from Onconova Therapeutics, Inc.; M. Maniar, employed by Onconova Therapeutics, Inc.

Ethics approval

The Institutional Animal Care and Usage Committee (IACUC) of Long Island University (Brooklyn Campus) approved the experimental protocol for the animal experiments. All animal procedures were conducted in accordance with the United States National Research Council “Guide for the Care and Use of Laboratory Animals”.

References

  1. 1.
    Perumal D, Kuo PY, Leshchenko VV, Jiang Z, Divakar SK, Cho HJ, Chari A, Brody J, Reddy MV, Zhang W, Reddy EP, Jagannath S, Parekh S. Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 exerts potent anticancer activity against multiple myeloma. Cancer Res. 2016;76:1225–36.CrossRefGoogle Scholar
  2. 2.
    Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015;56:3320–8.CrossRefGoogle Scholar
  3. 3.
    Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MAS, Chen-Kiang S. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 2006;66:7661–7.CrossRefGoogle Scholar
  4. 4.
    Athuluri-Divakar S, Ramana Reddy MV, Cosenza SC, Baker SJ, Purohit V, Gunda V, Singh PK, Reddy EP. Dual targeting of ARK5 and CDK4 pathways with ON 123300 as a therapeutic strategy for colorectal carcinoma. Cancer Res. 2016;76(Supplement):3029.CrossRefGoogle Scholar
  5. 5.
    Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41:329–42.CrossRefGoogle Scholar
  6. 6.
    Bonate PL. Gender-related differences in xenobiotic metabolism. J Clin Pharmacol. 1991;31:684–90.CrossRefGoogle Scholar
  7. 7.
    Wilson K. Sex-related differences in drug disposition in man. Clin Pharmacokinet. 1984;9:189–202.CrossRefGoogle Scholar
  8. 8.
    Gustafsson J, Stenberg A. Irreversible androgenic programming at birth of microsomal and soluble rat liver enzymes active on androstene-3,17-dione and 5alpha-androstane-3alpha,17beta-diol. J Biol Chem. 1974;249:711–8.Google Scholar
  9. 9.
    National Research Council. Guide for the care and use of laboratory animals. 8th ed. Washington, DC: The National Academies Press; 2011.Google Scholar
  10. 10.
    Obach S. Prediction of human clearance of twenty nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27:1350–9.Google Scholar
  11. 11.
    Piao Y, Liu Y, Xie X. Change trends of organ weight background data in Sprague Dawley rats at different ages. J Toxicol Pathol. 2013;26:29–34.CrossRefGoogle Scholar
  12. 12.
    Kajbaf M, Ricci R, Zambon S, Fontana S. Contribution of rat intestinal metabolism to the xenobiotics clearance. Eur J Drug Metab Pharmacokinet. 2013;38:33–41.CrossRefGoogle Scholar
  13. 13.
    Ren C, Maniar M. Liver microsomal stability of ON 123300 and identification of metabolites. Poster presentation at the 2017 AAPS Annual Meeting and Exposition; November 12-16, 2017; San Diego, CA. Poster W4103.Google Scholar
  14. 14.
    Tateishi T, Watanabe M, Nakura H, Tanaka M, Kumai T, Kobayashi S. Sex- or age-related differences were not detected in the activity of dihydropyrimidine dehydrogenase from rat liver. Pharmacol Res. 1997;35:103–6.CrossRefGoogle Scholar
  15. 15.
    Aiba T, Yoshinaga M, Ishida K, Takehara Y, Hashimoto Y. Intestinal expression and metabolic activity of the CYP3A subfamily in female rats. Biol Pharm Bull. 2005;28:311–5.CrossRefGoogle Scholar
  16. 16.
    Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol. 2009;76:215–28.CrossRefGoogle Scholar
  17. 17.
    Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther. 1997;73:147–71.CrossRefGoogle Scholar
  18. 18.
    McLure JA, Miners JO, Burkitt DJ. Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol. 2000;49:453–61.CrossRefGoogle Scholar
  19. 19.
    El-Kattan A, Varma V. Navigating transporter sciences in pharmacokinetics characterization using extended clearance classification system (ECCS). Drug Metab Dispos. 2018;46:729–39.CrossRefGoogle Scholar
  20. 20.
    Varma MV, Bi YA, Kimoto E, Lin J. Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion transporting polypeptide 1B1 substrates using a mechanistic net-effect model. J Pharmacol Exp Ther. 2014;351:214–23.CrossRefGoogle Scholar
  21. 21.
    Kimoto E, Bi YA, Kosa RE, Tremaine LM, Varma MVS. Hepatobiliary clearance prediction: species scaling from monkey, dog and rat and in vitro-in vivo extrapolation of sandwich cultured human hepatocyte using 17 drugs. J Pharm Sci. 2017;106:2795–804.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Pharmaceutical SciencesLong Island UniversityBrooklynUSA
  2. 2.Onconova Therapeutics, Inc.NewtownUSA

Personalised recommendations